About this Series

In the United States, bladder cancer ranks as the fourth most common cancer in men, striking roughly three times more men than women. With a median age of 72 at diagnosis, this patient population often faces age-related comorbidities. In many, decreased renal function excludes them from the most effective adjuvant chemotherapies.

The approvals of five PD-1 and PD-L1 inhibitors for second-line therapy have dramatically altered the treatment landscape for cisplatin-ineligible patients, who for decades have had limited treatment options. For the approximately 20%-25% of patients who respond to immunotherapies, researchers report seeing durable response as well as low rates of toxicities.

In this series, experts from The Tisch Cancer Institute at Mount Sinai in New York City examine the complexities of treating patients with metastatic bladder cancer and discuss the important role that immunotherapy has begun to play in this disease.

Show More

Who's Who
More on Metastatic Bladder Cancer